Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients

BACKGROUND AND OBJECTIVES: Older adults are more susceptible to coronavirus disease 2019 (COVID-19). Interleukin-6 (IL-6) is an important cytokine in the cytokine release syndrome (CRS), and tocilizumab blocks the IL-6 receptor. The objective is to analyze the effect of tocilizumab on CRS in older p...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Lengnan, Liu, Xin, Zhou, Yangwei, Liu, Aihua, Xu, Xiaomao, Wang, Xiaoxia, Zhong, Xuefeng, Qiao, Yu, Wen, Li, Xi, Huan, Mao, Yonghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549770/
http://dx.doi.org/10.4103/imna.imna_5_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549770/
http://dx.doi.org/10.4103/imna.imna_5_22

Ejemplares similares